These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 33273050)

  • 41. Did Prasugrel and Ticagrelor Offer the Same Benefit in Patients with Acute Coronary Syndromes after Percutaneous Coronary Interventions Compared to Clopidogrel? Insights from Randomized Clinical Trials, Registries and Meta-analysis.
    Rodriguez AE; Rodriguez-Granillo AM; Ascarrunz SD; Peralta-Bazan F; Cho MY
    Curr Pharm Des; 2018; 24(4):465-477. PubMed ID: 29308737
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention.
    Kim Y; Jeong MH; An M; Cho K; Hong Y; Kim J; Ahn Y
    PLoS One; 2023; 18(2):e0278993. PubMed ID: 36821598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
    Roe MT; Cyr DD; Eckart D; Schulte PJ; Morse MA; Blackwell KL; Ready NE; Zafar SY; Beaven AW; Strickler JH; Onken JE; Winters KJ; Houterloot L; Zamoryakhin D; Wiviott SD; White HD; Prabhakaran D; Fox KA; Armstrong PW; Ohman EM;
    Eur Heart J; 2016 Jan; 37(4):412-22. PubMed ID: 26637834
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.
    Tigen MK; Özdil MH; Çinçin A; Gürel E; Sünbül M; Şahin A; Güçtekin T; Doğan Z; Sayar N; Özben B
    Anatol J Cardiol; 2021 Oct; 25(10):699-705. PubMed ID: 34622784
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
    Christ G; Siller-Matula JM; Francesconi M; Dechant C; Grohs K; Podczeck-Schweighofer A
    BMJ Open; 2014 Oct; 4(10):e005781. PubMed ID: 25361837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
    Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
    Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome.
    Yildirim M; Mueller-Hennessen M; Milles BR; Biener M; Hund H; Frey N; Giannitsis E; Salbach C
    J Am Heart Assoc; 2023 Aug; 12(16):e030879. PubMed ID: 37581388
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
    Zocca P; van der Heijden LC; Kok MM; Löwik MM; Hartmann M; Stoel MG; Louwerenburg JW; de Man FHAF; Linssen GCM; Knottnerus IL; Doggen CJM; van Houwelingen KG; von Birgelen C
    EuroIntervention; 2017 Nov; 13(10):1168-1176. PubMed ID: 29151439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
    Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
    Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends for and Clinical Factors Associated with Choice of Oral P2Y
    Jain N; Hunt SL; Cui H; Phadnis MA; Mahnken JD; Shireman TI; Dai J; Mehta JL; Rasu RS
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):511-521. PubMed ID: 31729588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prasugrel in the treatment of acute coronary syndrome.
    Spartalis M; Tzatzaki E; Spartalis E; Paschou SA; Athanasiou A; Iliopoulos DC; Siasos G; Voudris V
    Future Cardiol; 2020 Nov; 16(6):559-568. PubMed ID: 32390477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study.
    Soueid AE; Kassas I; Rade J; Kakouros N
    J Invasive Cardiol; 2021 Apr; 33(4):E263-E268. PubMed ID: 33794478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania.
    Cotoban AG; Udroiu CA; Vinereanu D
    Am J Ther; 2021 Apr; 28(3):e271-e283. PubMed ID: 33852478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
    D'Ascenzo F; DE Filippo O; Angelini F; Piroli F; DE Lio G; Bocchino PP; Baldetti L; Melillo F; Chieffo A; Saglietto A; Omedè P; Montefusco A; Conrotto F; de Ferrari GM
    Minerva Cardiol Angiol; 2023 Oct; 71(5):494-503. PubMed ID: 35332750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potent P2Y12 inhibitors versus clopidogrel to predict adherence to antiplatelet therapy after an acute coronary syndrome: insights from IDEAL-LDL.
    Kourti O; Konstantas O; Farmakis IΤ; Zafeiropoulos S; Psarakis G; Vrana E; Baroutidou A; Graidis S; Touriki AV; Tsolakidis C; Spyridaki K; Psathas T; Daniilidou A; Karvounis H; Giannakoulas G
    Rev Cardiovasc Med; 2022 Mar; 23(3):81. PubMed ID: 35345248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
    Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
    EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.
    Angerås O; Hasvold P; Thuresson M; Deleskog A; ÖBraun O
    Scand Cardiovasc J; 2016; 50(2):99-107. PubMed ID: 26564402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.